Arvinas’ (ARVN) chief medical officer Berkowitz sells $67,594 in stock

Arvinas' (ARVN) Chief Medical Officer Dr. David Berkowitz sold $67,594 worth of company stock in a recent transaction, as reported in regulatory filings. The transaction occurred on May 15, 2023, according to documents filed with the Securities and Exchange Commission (SEC). The sale was part of personal financial planning activities by the executive, which is a common practice among corporate officers managing their personal investment portfolios. Arvinas, a clinical-stage biotechnology company specializing in targeted protein degradation therapies, has seen significant stock price volatility in recent months as it advances its pipeline of novel treatments for various diseases. Insider stock sales, while legally distinct from insider trading, are closely monitored by investors as they may provide insights into how executives view their company's near-term prospects. Berkowitz's sale involved 1,000 shares of the company's common stock at an average price of $67.59 per share, according to the SEC Form 4 filing.